

IFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


Applicants: Van der Ploeg, Leonardus H. T. Chen, Howard
Y., Chen, Airu S.

Serial No. 10/603,249

Filed: June 25, 2003

For: MELANOCORTIN-3 RECEPTOR DEFICIENT CELLS,
NON-HUMAN TRANSGENIC ANIMALS AND
METHODS OF SELECTING COMPOUNDS WHICH
REGULATE BODY WEIGHT

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450



Art Unit: 1632

Examiner: To be assigned

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR 1.97

Sir:

1. In compliance with 37 C.F.R. 1.97, submitted on the attached form herewith is a list of patents, publications or other information which are requested to be made of record in this application. This Information Disclosure Statement is not an admission that any patent, publication or other information referred to herein is "prior art" for this invention. In accordance with 37 C.F.R. 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. 1.56(b).

2. In accordance with 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.


3. Applicants respectfully request that the Examiner initial the attached form after reviewing the pertinence of each reference.

4. Pursuant to 37 C.F.R. 1.98 (a)(2)(ii), copies of each cited U.S. patent and each U.S. patent application publication are not enclosed herewith.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on the date appearing below.

MERCK & CO., INC.

By Danilo J. Murante Date January 26, 2006



INFORMATION DISCLOSURE STATEMENT

5. Pursuant to 37 C.F.R. 1.98(d), copies of references listed on the attached form that were submitted to or cited by the Office in a related application upon which the instant application relies for an earlier filing date under 35 U.S.C. 120 are not enclosed. Related application(s) in which references were submitted to or cited by the Office are as follows:

RELATED APPLICATION		
U. S. SERIAL NUMBER	FILING DATE	MERCK CASE

If this is inconvenient, additional copies will be submitted upon request.

6. In accordance with 37 C.F.R. 1.97, (check one)

- ☐ the attached information is filed within three months of the filing date of the captioned case.
- ☒ the attached information is filed more than three months after the filing date but prior to the mailing of a first Office Action on the merits.
- ☐ the attached information is filed before the mailing of a first Office action after the filing of a request for continued examination under §1.114.
- ☐ the attached information is being filed more than three months after the filing date and after the mailing of a first Office Action on the merits, but before the mailing date of a Final Action, Notice of Allowance, or an action that otherwise closes prosecution in the application. The enclosed authorization is therefore given to charge Deposit Account No. 13-2755 for the fee required under 37 C.F.R. 1.17(p).
- ☐ each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement.
- ☐ each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart application *and this communication was not received by any individual designated in §1.56(c) more than thirty days prior to the filing of the information disclosure statement.*
- ☐ no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated under 37 C.F.R. 1.56(c) more than three months prior to the filing of this Statement.

Respectfully submitted,

Laura M. Ginkel

By: Laura M. Ginkel

Attorney _____ For Applicant(s)

Reg. No. 51,737

MERCK & CO., INC.

Patent Dept., RY60-30

P.O. Box 2000

Rahway, N.J. 07065-0907

(732)594-1932

Date: Jan. 26, 2006

INFORMATION DISCLOSURE

STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

5

COMPLETE IF KNOWN

Application Number	10/603,249
---------------------------	------------

Filing Date	June 25, 2003
--------------------	---------------

First Named Inventor	Van der Ploeg, Leonardus, H.T.
-----------------------------	--------------------------------

Group Art Unit	1632
----------------	------

Examiner Name	To be assigned
---------------	----------------

Attorney Docket Number 20561 YDA

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., -7/12/2005

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			COMPLETE IF KNOWN		
			Application Number	10/603,249	
			Filing Date	June 25, 2003	
			First Named Inventor	Van der Ploeg, Leonardus, H.T.	
			Group Art Unit	1632	
			Examiner Name	To be assigned	
Sheet	2	of	5	Attorney Docket Number	20561 YDA

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
	G	DESARNAUD, ET AL., "Molecular cloning, functional expression and pharmacological characterization of a mouse melanocortin receptor gene", Biochem. Journal, Vol. 299, No. 2, pages 367-373, 1994.
	H	ROSELLI-REHFUSS, ET AL., "Identification of a receptor for melanotropin and other proopiomelanocortin peptides in the hypothalamus and limbic system", Proc. Natl. Acad. Sci., Vol. 90, pages 8856-8860, 1993.
	I	GANTZ, ET AL., "Molecular Cloning of a Novel Melanocortin Receptor", J. Biol. Chem., Vol. 268, No. 11, pages 8246-8250, 1993.
	J	MOUNTJOY, ET AL., "Localization of the Melanocortin-4 Receptor (MC4-R) in Neuroendocrine and Autonomic Control Circuits in the Brain", Molecular Endocrinology, Vol. 8, No. 10, pages 1298-1308, 1994.
	K	TYBULEWICZ, VICTOR L.J., ET AL., "Neonatal Lethality and Lymphopenia in Mice with a Homozygous Disruption of the c-abl Proto-Oncogene", Cell, Vol. 65, pages 1153-1163, 1991.
	L	HAYNES, ET AL., "Interactions Between the Melanocortin System and Leptin in Control of Sympathetic Nerve Traffic", Hypertension, Vol. 33, Part II, pages 542-547, 1999.
	M	DINULESCU, ET AL., " <i>Mahogany (mg)</i> stimulates feeding and increases basal metabolic rate independent of its suppression of <i>agouti</i> ", Proc. Natl. Acad. Sci., Vol. 95, pages 12707-12712, 1998.
	N	GIROS, ET AL., "Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter", Nature, Vol. 379, pages 606-612, 1996.
	O	CONE, ET AL., "The Melanocortin Receptors: Agonists, Antagonists, and the Hormonal Control of Pigmentation", Recent Progress in Hormone Research, Vol. 51, pages 287-318, 1996.
	P	BOSTON, ET AL., "Independent and Additive Effects of Central POMC and Leptin Pathways on Murine Obesity", Science, Vol 278, pages 1641-1644, 1997.
	Q	CHEN, ET AL., "Altered Expression of Agouti-Related Protein and Its Colocalization with Neuropeptide Y in the Arcuate Nucleus of the Hypothalamus during Lactation", Endocrinology, Vol. 140, pages 2645-2650, 1999.
	R	CUNNINGHAM, ET AL., "Leptin's Actions on the Reproductive Axis: Perspectives and Mechanisms", Biology of Reproduction, Vol. 60, pages 216-222, 1999.
	S	ELIAS, ET AL., "Leptin Activates Hypothalamic CART Neurons projecting to the Spinal Cord", Neuron, Vol. 21, pages 1375-1385, 1998.
	T	FAN, ET AL., "Role of melanocortinergic neurons in feeding and the agouti obesity syndrome", Nature, Vol. 385, pages 165-168, 1997.
	U	FONG, ET AL., "ART (Protein Product of Agouti-Related Transcript) as an Antagonist of MC-3 and MC-4 Receptors", Biochemical and Biophysical Research Communications, Vol. 237, pages 629-631, 1997.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., -7/12/2005

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			COMPLETE IF KNOWN		
			Application Number	10/603,249	
			Filing Date	June 25, 2003	
			First Named Inventor	Van der Ploeg, Leonardus, H.T.	
			Group Art Unit	1632	
			Examiner Name	To be assigned	
Sheet	3	of	5	Attorney Docket Number	20561 YDA

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
	V	FINN, ET AL., "The Stimulatory Effect of Leptin on the Neuroendocrine Reproductive Axis of the Monkey", Endocrinology, Vol. 139, No. 11, pages 4652-4662, 1998.
	W	GUAN, ET AL., "Evidence of altered hypothalamic pro-opiomelanocortin/neuropeptide Y mRNA expression in tubby mice", Molecular Brain Research, Vol. 59, pages 273-279, 1998.
	X	GUNN, ET AL., "The mouse <i>mahogany</i> locus encodes a transmembrane form of human attractin", Nature, Vol. 398, pages 152-156, 1999.
	Y	HADLEY, ET AL., "Discovery and Development of Novel Melanogenic Drugs", Pharmaceutical Biotechnology, Chapter 25, pages 575-595, 1998.
	Z	HAHN, ET AL., "Coexpression of AgRP and NPY in fasting-activated hypothalamic neurons", Nature Neuroscience, Vol. 1, No. 4, pages 271-272, 1998.
	AA	KALRA, ET AL., "Interacting Appetite-Regulating Pathways in the Hypothalamic Regulation of Body Weight", Endocrine Reviews, Vol 20. No. 1, pages 68-100, 1999.
	AB	LU, ET AL., "Agouti protein is an antagonist of the melanocyte-stimulating-hormone receptor", Nature, Vol. 371, pages 799-802, 1994.
	AC	MARSH, ET AL., "Response of melanocortin-4 receptor-deficient mice to anorectic and orexigenic peptides", Nature Genetics, Vol. 21, pages 119-122, 1999.
	AD	MILTENBERGER, ET AL., "The Role of the agouti Gene in the Yellow Obese Syndrome", J. Nutr, Vol. 127, pages 1902S-1907S, 1997.
	AE	MOUNTJOY, ET AL., "Obesity, Diabetes and Functions for Proopiomelanocortin-derived Peptides", Molecular and Cellular Endocrinology, Vol. 128, pages 171-177, 1997.
	AF	NAGLE, ET AL., "The <i>mahogany</i> protein is a receptor involved in suppression of obesity", Nature, Vol. 398, pages 148-151, 1999.
	AG	ROBERTS, ET AL., "The New Obesity Genes", Nutrition Reviews, Vol. 54, No. 2, pages 41-49, 1996.
	AH	SHUTTER, ET AL., "Hypothalamic expression of ART, a novel gene related to agouti, is up-regulated in <i>obese</i> and <i>diabetic</i> mutant mice", Genes & Development, Vol. 11, pages 593-602, 1997
	AI	VON KOCH, ET AL., "Generation of APLP2 KO Mice and Early Postnatal Lethality in APLP2/APP Double KO Mice", Neurobiology of Aging, Vol. 18, pages 661-669, 1997.
	AJ	YANG, ET AL., "Characterization of Agouti-Related Protein Binding to Melanocortin Receptors", Molecular Endocrinology, Vol. 13, No. 1, pages 148-155, 1999.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., -7/12/2005

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			COMPLETE IF KNOWN		
			Application Number	10/603,249	
			Filing Date	June 25, 2003	
			First Named Inventor	Van der Ploeg, Leonardus, H.T.	
			Group Art Unit	1632	
			Examiner Name	To be assigned	
Sheet	4	of	5	Attorney Docket Number	20561 YDA

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
	AK	YEN, ET AL., "Obesity, diabetes, and neoplasia in yellow A -mice: ectopic expression of the <i>agouti</i> gene FASEB J., Vol. 8, pages 479-488, 1994.
	AL	KASK, A., ET AL., "Discovery of a Novel Superpotent and Selective Melanocortin-4 Receptor Antagonist (HS024): Evaluation <i>in Vitro</i> and <i>in Vivo</i> ", Endocrinology, Vol. 139, No. 12, pages 5006-5014, 1998.
	AM	HUSZAR, D., ET AL., "Targeted Disruption of the Melanocortin-4 Receptor Results in Obesity in Mice", Vol. 88, pages 131-141, 1997.
	AN	CAMPBELL, ET AL., "Totipotency or Multipotentiality of Cultured Cells: Applications and Progress", Theriogenology, Vol. 47, pages 63-72, 1997.
	AO	BRADLEY, ET AL., "Modifying the Mouse: Design and Desire", Biotechnology, Vol. 10, pages 534-539, 1992.
	AP	MULLINS, ET AL., "Perspectives Series: Molecular Medicine in Genetically Engineered Animals", Clin. Invest., Vol. 97, No. 7, pages 1557-1560, 1996.
	AQ	KUEHN, ET AL., "A potential animal model for Lesch-Nyhan syndrome through introduction of HPRT mutations into mice", Vol. 326, pages 295-298, 1987.
	AR	JAENISCH, R. "Transgenic Animals", Science, Vol. 240, pages 1468-1474, 1988.
	AS	SIGMUND, ET AL. "Viewpoint: Are Studies in Genetically Altered Mice Out of Control?", Arterioscler Thromb Vasc Biol., Vol. 20, pages 1425-1429, 2000.
	AT	MOENS, ET AL. "Defects in heart and lung development in compound heterozygotes for two different targeted mutations at the <i>N-myc</i> locus", Development, Vol. 119, pages 485-499, 1993.
	AU	JACKS, ET AL., "Effects of an RB mutation in the mouse", Nature, Vol. 359, pages 295-300, 1992.
	AV	CAPECCHI, ET AL., "The New Mouse Genetics: Altering the Genome by Gene Targeting", Trends in Genetics, Vol. 5, No. 3, pages 70-76, 1989.
	AW	DONEHOWER, ET AL., "Effects of Genetic Background on Tumorigenesis in p53-Deficient Mice", Molecular Carcinogenesis, Vol. 14, pages 16-22, 1995.
	AX	BIOTECH DICTIONARY, "Hemizygous definition and Hemizygous gene definition", BioTech Resources and Indiana University, 2002.
	AY	CHEN, ET AL., "Exocrine Gland Dysfunction in MC5-R-Deficient Mice: Evidence for Coordinated Regulation of Exocrine Gland Function by Melanocortin Peptides", Cell, Vol. 91, pages 789-798, 1997.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., -7/12/2005

Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., -7/12/2005